Russian courts have tightened arbitrability rules for pharmaceutical corporate disputes. What in-house counsel needs to know. Make an enquiry.
Following a sustained period of judicial and legislative activity affecting the enforceability of arbitration clauses in Russian corporate contracts, foreign companies operating in the pharmaceuticals sector now face a materially altered risk landscape for dispute resolution. The changes, which have consolidated across Russian court practice through the period leading to early 2026, narrow the circumstances in which arbitration clauses inserted into Russian law-governed shareholders' agreements and corporate charters can reliably divert a corporate dispute away from the Russian state commercial courts. For in-house counsel managing Russian pharmaceutical subsidiaries or joint ventures, the practical consequence is direct: dispute resolution clauses drafted on assumptions that were reasonable five years ago may no longer function as intended.
The core shift concerns the doctrine of arbitrability as applied to corporate disputes. Russian law has long drawn a distinction between ordinary commercial disputes — where freedom to agree on arbitration is largely preserved — and disputes that arise from the internal life of a legal entity, including shareholder rights, management authority, and the validity of corporate decisions. The latter category has been subjected to progressively tighter constraints.
In principle, Russian law does not prohibit all arbitration of corporate disputes. Certain categories of dispute involving Russian legal entities may be referred to qualifying arbitral institutions, provided specific procedural conditions are met. In practice, however, state courts have applied a demanding standard when assessing whether these conditions are satisfied. Agreements that do not satisfy the technical requirements — including rules on the seat of arbitration, applicable institutional rules, and the composition of the tribunal — have been treated as unenforceable as to their dispute resolution provisions, with the consequence that the Russian arbitrazh court retakes jurisdiction.
The pharmaceutical sector introduces additional complexity. Several factors converge to create a distinct arbitrability problem for companies in this space: the heightened regulatory presence of Roszdravnadzor and related government bodies; the frequency of joint ventures between foreign capital and Russian state-connected entities; and the post-2022 evolution of parallel import rules, which has altered the commercial architecture of many distribution and licensing arrangements and, with it, the underlying corporate governance structures. Where one party to a shareholders' agreement is a state-connected entity, the appetite of Russian courts to uphold an arbitration clause against that party has been, in the prevailing experience of practitioners advising in this sector, notably limited.
"The question is no longer whether an arbitration clause can exist in a Russian pharmaceutical joint venture agreement — it can. The question is whether, when the clause is tested under pressure, a Russian court will treat it as dispositive." — Stanislav Lastovsky, Senior Lawyer, Practice Lead — Restructuring & Insolvency, Vetrov & Partners
For in-house counsel reviewing dispute resolution provisions in existing Russian pharmaceutical contracts, an early assessment of clause enforceability under current Russian court practice can prevent the loss of forum control at the moment it matters most — make an enquiry: info@vetrovpartners.com |
The impact of this doctrinal shift is not uniform. Its practical weight falls most heavily on three categories of foreign company with Russian pharmaceutical interests.
The first category is foreign shareholders in Russian joint ventures where the co-venturers include a Russian state-connected entity or a company subject to strategic sector controls. In such structures, the Russian party has an asymmetric advantage in domestic proceedings and an asymmetric incentive to resist arbitral jurisdiction. Arbitration clauses negotiated at the outset on the assumption of mutual enforceability may, in practice, be available only to the party least likely to invoke them.
The second category is foreign companies that hold pharmaceutical distribution or licensing rights through a Russian subsidiary, where the subsidiary's corporate governance documents — the charter and any shareholders' agreement — contain dispute resolution clauses adopted in an earlier period. These documents should be reviewed against the current standard. A clause that was standard-form acceptable in 2018 or 2019 may fail the current technical requirements without having been amended.
The third category is foreign creditors and minority shareholders in pharmaceutical companies that are encountering financial difficulty. Foreign companies holding Russian assets should be aware that, under the current judicial approach, insolvency-adjacent corporate disputes — challenges to management decisions, disputes over asset transfers, claims relating to dividend decisions — are among the categories where courts have been most willing to assert exclusive jurisdiction regardless of an arbitration clause. The window for preserving contractual forum-selection rights can close rapidly once insolvency proceedings become a live prospect, leaving a creditor or minority shareholder reliant on Russian court procedure with limited preparation time.
The Corporate Governance practice page sets out the firm's broader approach to advising foreign shareholders in Russian entities on governance risk.
For a more detailed analysis of the arbitrability doctrine itself, see Corporate disputes: arbitration clauses in Russian law contracts and the extended deep-dive on arbitration clause enforceability.
The practical response to this development operates at three levels, each appropriate to a different stage of the commercial relationship.
For companies at the contract-drafting stage — including those establishing a new joint venture or restructuring an existing one — the priority is ensuring that any arbitration clause is drafted to satisfy the current Russian technical requirements, rather than simply reproducing institutional language from a foreign template. This means a careful assessment of the proposed arbitral institution's qualification under Russian law, the seat of arbitration, and the procedural rules that would govern any tribunal. Where a state-connected Russian party is involved, counsel should also address the risk that the clause may be selectively effective — available to the foreign party to invoke, but susceptible to challenge if the Russian party is the respondent.
For companies reviewing existing contracts, the relevant question is not simply whether an arbitration clause is present, but whether it would be upheld by a Russian arbitrazh court if challenged. This is a fact-specific assessment that requires analysis of the current clause against the evolving court practice. It also requires a judgment about the realistic alternative: if the clause were set aside, what would state court proceedings look like, and is the company adequately prepared for that forum?
For companies already in a dispute or approaching one, the timing question is critical. A party that moves first in the appropriate forum — whether arbitral or judicial — often acquires a procedural advantage that is difficult for the other side to overcome. Parallel proceedings, anti-suit measures, and interim relief applications all depend heavily on which proceeding was commenced first and in which forum. This is not an area where a watching brief is an appropriate strategy.
The intersection of pharmaceutical sector governance with arbitration law also has implications for Restructuring & Insolvency scenarios — particularly where a foreign creditor's enforcement position is affected by the corporate structure of a distressed pharmaceutical entity. The firm's restructuring and insolvency practice regularly advises in precisely this intersection, including in matters recorded in the Matters Hub.
If your company holds pharmaceutical assets in Russia under a shareholders' agreement or joint venture structure with arbitration provisions, discuss the matter in confidence: info@vetrovpartners.com |
Q: What specifically changed in Russian court practice on arbitration clauses in corporate disputes?
A: The change is doctrinal rather than a single statutory amendment. Russian courts have progressively narrowed the category of corporate dispute that may be resolved by arbitration, applying a demanding set of technical requirements to arbitration clauses in shareholders' agreements and corporate charters. Where those requirements are not met — including rules on the qualifying arbitral institution, the seat of the proceedings, and applicable procedural rules — courts have asserted jurisdiction over the dispute regardless of what the parties agreed. As of early 2026, this approach has become the prevailing standard in the Russian arbitrazh court system, and practitioners advising in the pharmaceutical sector report that state-connected counterparties are increasingly willing to test it.
Q: Which foreign companies in the pharmaceutical sector are most exposed to this development?
A: Exposure is highest for three groups: foreign shareholders in joint ventures with Russian state-connected entities, where the Russian party can exploit asymmetric access to domestic courts; foreign companies holding pharmaceutical rights through Russian subsidiaries with outdated corporate governance documents; and foreign minority shareholders or creditors in pharmaceutical companies approaching financial difficulty, where insolvency-adjacent corporate disputes are among the categories most resistant to arbitral jurisdiction. Companies in any of these categories should treat a review of their dispute resolution provisions as a matter of current priority rather than a deferred compliance exercise.
Q: What is the most important immediate step for in-house counsel managing a Russian pharmaceutical subsidiary?
A: The most useful immediate step is a focused review of the dispute resolution clause in the company's shareholders' agreement or joint venture charter against the current Russian legal standard — not the standard that applied when the document was drafted. That review should produce a clear answer to two questions: would this clause be upheld by a Russian arbitrazh court if challenged today, and if not, what is the firm's procedural position in state court proceedings? In the pharmaceutical sector, the answer to both questions is frequently more unfavourable than counsel expects, and the earlier the assessment is made, the more options are available to address the gap.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry